Did you know that your version of Internet Explorer is out of date?
To get the best possible experience using our website we recommend downloading one of the below web browsers.

Internet Explorer 9, Firefox, Chrome, or Safari.

Treatment Access News

Health Canada has issued a Notice of Compliance for Odefsey

february 16, 2017

read more

CanPrEP Submits Supplemental Recommendations on Truvada for HIV PrEP to pCPA

january 4, 2017

CanPrEP is submitting this letter as a supplement to our previous submission to the pan-Canadian Pharmaceutical Alliance on Truvada (fixed dose oral combination emtricitabine/tenofovir disoproxil fumarate; FTC/TDF) for HIV pre-exposure prophylaxis (PrEP). This supplemental submission is intended to address issues...

read more

CTAC’S Preliminary Analysis of CDEC Recommendation on Truvada for HIV PrEP

september 8, 2016

On 26 August 2016, the Canadian Drug Expert Committee (CDEC) published its Final Recommendation for Truvada as HIV pre-exposure prophylaxis (PrEP)...

read more

CDEC Recommends Reimbursement of Truvada for HIV PrEP Under Public Drug Plans

august 26, 2016

The CADTH Canadian Drug Expert Committee (CDEC) recommends that emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) be reimbursed for use as pre-exposure prophylaxis (PrEP) of human immunodeficiency virus type 1 (HIV-1) in combination with safer sex practices to reduce the risk...

read more